Cardiovascular risk scores in axial spondyloarthritis versus the general population: A cross-sectional study.

Like Comment
Cardiovascular (CV) morbidity and mortality are increased in axial spondyloarthritis (axSpA). We conducted a cross-sectional study evaluating the 10-year atherosclerotic cardiovascular disease (ASCVD) risk in axSpA compared to the general US population.We included 211 adults 40-75 years old with ankylosing spondylitis (AS) or non-radiographic axSpA from two sites, who had available data on comorbidities, medication use, blood pressure measures, and laboratory cholesterol values. We matched 4:1 to general population comparators from the 2009-2014 National Health and Examination Survey (NHANES) cycles on age, sex, and race. We estimated the prevalence ratio for a 10-year ASCVD risk score ≥7.5% comparing axSpA and matched NHANES comparators using conditional Poisson regression.Overall, subjects were 53.9 ± 11.2 years old, 69% were male, and 74% were white. The mean 10-year ASCVD risk score was 6.7 ± 6.9% for those with axSpA and 9.0 ± 10.5% for NHANES comparators. Compared to those with axSpA, the prevalence of current smoking and diabetes was higher among NHANES comparators. The estimated prevalence ratio for a 10-year ASCVD risk score ≥7.5% comparing those with axSpA and their age-, sex-, and race-matched comparators was 0.96 (95% CI, 0.74-1.24).The prevalence of a 10-year ASCVD risk score ≥7.5% was not significantly different comparing axSpA patients and those drawn from the general population, who were similar in terms of age, sex, and race. Future studies should focus on improved CV risk prediction in axSpA, as underestimation by a general population risk score may potentially explain these results.


Click here to read the full article @ The Journal of rheumatology
Go to the profile of ClinOwl

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2212 Contributions
1 Followers
0 Following

No comments yet.